[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Astellas Institute for Regenerative Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100649370","phase-1-a-study-about-the-safety-of-a-single-asp2020-eye-injection-and-if-it-helps-people-with-vision-loss-from-stargardt-type-eye-conditions-100649370",false,"NCT07734064","A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions","A Phase 1b, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Subretinal Dose of ASP2020 in Participants With Macular Dystrophies With a Stargardt-type Clinical Presentation","Inclusion Criteria:\n\n* Documented clinical diagnosis of macular dystrophy with a STGD-type clinical presentation and molecular confirmation, defined as either:\n\n  * STGD: presence of biallelic (pathogenic or likely pathogenic) ABCA4 variants, or one definite disease-causing ABCA4 variant together with a typical phenotype consistent with STGD.\n  * STGD-like macular dystrophy: presence of one or more pathogenic variants in a gene known to cause macular dystrophy, as appropriate for its expected inheritance mode.\n* Sufficiently clear ocular media and adequate pupillary dilation to allow for all imaging procedures.\n* Intraocular pressure (IOP) of ≤ 21 mmHg\n* Participant has a spherical equivalent refractive error between +8.00 D and -10.00 D.\n* BCVA ranging from 20\u002F500 to 20\u002F40 (equivalent to 15 to 70 ETDRS letters)\n\n  * For participants in the \\> 20\u002F80 to ≤ 20\u002F40 BCVA range (moderate visual impairment \\[MVI\\]): presence of a visible definite or probable residual ellipsoid zone (EZ) on SD-OCT, and a total retinal SD-OCT central subfield thickness ≥ 150 micrometers (µm)\n  * For participants in the ≥ 20\u002F500 to ≤ 20\u002F80 BCVA range (severe visual impairment): Presence of a residual ONL within the macular optical coherence tomography (OCT) scan area and Evidence of RPE disease\u002Fdamage by means of SD-OCT (hypertransmission defect) and\u002For FAF imaging (questionably decreased autofluorescence\u002Fdefinitely decreased autofluorescence).\n\nExclusion Criteria:\n\n* Participant has a known history of significant systemic disease that could impact ocular health or confound study assessments, based on medical history or prior clinical documentation.\n* Participant has an autoimmune condition that requires treatment with immunomodulatory therapy and\u002For biologics that cause immunosuppression.\n* Participant has known diagnosis of diabetes mellitus with a documented glycated hemoglobin (HbA1c) value ≥ 7% 3 months prior to screening and based on available medical records.\n* Participant has a history or evidence of severe cardiac disease, cardiovascular or cerebrovascular disease, including a history of stroke within 12 months prior to screening.\n* Participant has any complicating systemic disease or active malignancy.\n* Participant has a known history of any systemic or metabolic condition, or physical examination finding that may significantly affect ocular health or interfere with the interpretation of study assessments.\n* Participant has presence of another known or suspected molecular diagnosis of macular or retinal disease that could confound interpretation of study outcomes, indicate a second concomitant retinal condition, or suggest a different etiology for the macular disease.\n* Participant has macular atrophy due to any cause other than a genetically or clinically confirmed diagnosis of STGD or STGD-like macular dystrophy.\n* Participant has evidence or history of choroidal neovascularization.\n* Participant has diagnosis of any form of uncontrolled glaucoma (for high-tension glaucoma IOP \\> 25 mmHg).\n* Participant has a history of steroid-induced IOP elevation or known steroid responder status.\n* Participant has and\u002For is receiving treatment for thyroid eye disease.\n* Participant has diabetic retinopathy in excess of mild nonproliferative diabetic retinopathy\n* Participant has any other disease(s) affecting the optic nerve.\n* Participant has a history of anterior or posterior uveitis and\u002For presence of intraocular inflammation (trace anterior chamber cell or flare), or history of idiopathic or autoimmune-associated uveitis in either eye.\n* Participant has media opacities impeding the visualization of the fundus and\u002For the reliable performance of the visual function tests required by the protocol.\n* Participant has aphakia.\n* Participant has a clinically significant epiretinal membrane or evidence of clinically significant vitreomacular traction syndrome.\n* Participant has any other disorders which could interfere with or confound visual acuity and other ocular assessments, including OCT or FAF.\n* Participant has history of any of the following procedures: posterior vitrectomy, retinal detachment surgery, glaucoma filtering surgery, glaucoma drainage device implantation, selective laser trabeculoplasty, full-thickness or partial- thickness corneal transplant.\n* Participant has had any intraocular surgery within 3 months of screening.\n* Participant has a history of intraocular metallic foreign bodies.\n* Participant has received any treatment including gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, or any prior intravitreal treatment for any indication in either eye that may be considered to potentially interfere with the study participation or its conduct.\n* Participant has received within 1 month prior to screening or is receiving concomitant treatment with any ocular or systemic medication known to be toxic to the lens, retina, or optic nerve.\n* Participant has received any investigational therapy within 3 months prior to screening.\n* Participant has any condition, which makes the participant unsuitable for study participation.","ALL","6 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads to loss of central vision, which can make it harder to read, recognize faces or see fine details. What's seen out of the corner of the eye (peripheral vision) is mostly unaffected. Stargardt disease (STGD) is a type of macular dystrophy which is caused by 1 faulty gene (ABCA4). Vision loss most typically begins in childhood or teenage years but may also develop in adulthood. As well as STGD, there are other macular dystrophies that look very similar to STGD and are called STGD-like macular dystrophies. These are caused by many other different genes. Together, STGD and STGD-like conditions can be called STGD-type macular dystrophies.\n\nThis is an early development study of ASP2020 in adults, teenagers, and children with STGD-type macular dystrophies. ASP2020 are human stem cells which have been changed into cells found in the macula. In this study ASP2020 will be given to people for the first time. The main aim of the study is to check the safety of ASP2020 and how well people tolerate it. Other aims are to learn if people have an immune reaction to ASP2020, and if there are signs that the stem cells replace damaged cells in the retina, and vision improves for people with STGD-type macular dystrophies.\n\nASP2020 will be given as a single injection into the eye, under the retina. This requires a surgical procedure where the person is put to sleep by a general anesthetic. At the end of surgery, a steroid will be injected into the eye to reduce any swelling.\n\nThe study has 2 parts. In Part 1, different small groups will receive a lower to higher dose of ASP2020. This is done to find a suitable dose to use in Part 2. The adults will receive the lower dose and higher dose before the teenagers. There will be a 6-month gap between the last adult receiving the lower dose of ASP2020 and the first teenager receiving the same lower dose. This will also happen for the last adult receiving the higher dose of ASP2020 and the first teenager receiving the higher dose of ASP2020. Any medical problems will be recorded for each dose in each group. Children will not receive ASP2020 in Part 1.\n\nIn Part 2, different groups of adults, teenagers and children will receive the most suitable dose of ASP2020 worked out from Part 1.\n\nPeople will be in the study for about 1 year and they will visit the clinic several times. In both parts of the study, safety checks will be done at each visit, and the study doctors will continue to check for any medical problems throughout the study. Various eye tests and eye imaging will be done throughout the study. Blood tests will also be done at some of the visits during the study.",[26,27,28],"Stargardt Disease","Stargardt Macular Dystrophy","Stargardt-like Macular Dystrophy",[30,31,32,33,34,35,36,37],"Macular Dystrophies","Stargardt type","ABCA4 related STGD","STGD-like macular dystrophies","Safety","STGD","STGD-like","STGD-type","NOT_YET_RECRUITING","2026-07-24",{"date":41,"type":42},"2026-07-29","ACTUAL",{"date":44,"type":20},"2026-07-31",{"date":46,"type":20},"2029-09-30",{"name":48,"class":49},"Astellas Institute for Regenerative Medicine","INDUSTRY",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100299446","phase-1-a-study-of-the-safety-and-tolerability-of-asp7317-in-senior-adults-who-are-losing-their-clear-sharp-central-vision-due-to-geographic-atrophy-secondary-to-dry-age-related-macular-degeneration-100299446","NCT03178149","A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration","Inclusion Criteria:\n\nGeneral Inclusion Criteria\n\n* Participant must be willing to take tacrolimus and willing to discontinue any medications that have a known strong interaction with tacrolimus.\n* Participant is able and willing to undertake all scheduled visits and assessments up to the week 52 visit.\n* Participant who is taking an antidepressant must be on a stable and effective dosage and must be willing to take it reliably for as long as it is required.\n* Participant must be willing and medically suitable to undergo monitored anesthesia care during the vitrectomy and subretinal injection.\n* Participant agrees to conform to local and institutional policies regarding active COVID-19 infections.\n* Participant agrees not to participate in another interventional study until the 52-week visit has been completed.\n* Female participant is not pregnant or at least 1 of the following conditions apply:\n\n  * Not a woman of childbearing potential (WOCBP)\n  * WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 52 weeks after investigational product (IP) administration.\n* Female participant must agree not to breastfeed starting at screening and throughout the study period and for 52 weeks after IP administration.\n* Female participant must not donate ova starting at first dose of IP and throughout the study period and for 52 weeks after IP administration.\n* Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 52 weeks after IP administration.\n* Male participant must not donate sperm during the treatment period and for 52 weeks after IP administration.\n* Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 52 weeks after IP administration.\n\nOcular Inclusion Criteria: Study Eye (Both Groups 1 and 2)\n\n* Participant has bilateral AMD and geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) in the study eye. GA is defined as sharply demarcated areas of loss of the retinal pigment epithelial\u002Fepithelium (RPE). While having bilateral GA remains the preferred enrollment criterion, it is not a requirement and GA only in the study eye is admissible, as long as both eyes exhibit AMD.\n* Participant has no known history of choroidal neovascularization (CNV) (wet AMD) in either eye prior to enrollment in the trial and no evidence of prior or active CNV with optical coherence tomographyangiography (OCT-A) or indocyanine green angiography (ICG-A), as assessed by the reading center.\n* Participant has absence of exudation as assessed by fluorescein angiography (FA) and spectral domain-optical coherence tomography (SD-OCT).\n* Participant has sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging.\n* Participant is pseudophakic.\n\nOcular Inclusion Criteria: Study Eye (Group 1 only)\n\n* For cohort 1, the participant has a BCVA between light perception and \\\u003C\u002F=23 Early Treatment Diabetic Retinopathy study (ETDRS) letters at the screening visit. For cohorts 2 and 3, the participant has a BCVA score between 15 (\\>\u002F= 20\u002F500) and 37 (\\\u003C\u002F=20\u002F200) ETDRS letters at the screening visit.\n* Participant has the total GA area \\\u003C\u002F=30.5 mm\\^2 (\\\u003C\u002F=12 disc areas \\[DA\\]).\n\nOcular Inclusion Criteria: Study Eye (Group 2 only)\n\n* Participant has BCVA score between 38 (\\>20\u002F200) and 65 (\\\u003C\u002F=20\u002F50) ETDRS letters during the screening visit.\n* Participant has the total GA area of \\>\u002F= 2.54 mm\\^2 and \\\u003C\u002F= 20.4 mm\\^2 (\\>\u002F=1 and \\\u003C\u002F=8 DA, respectively) and must reside completely within the fundus autofluorescence (FAF) imaging field (Field 2 to 30 degree image centered on the fovea).\n* Participant has a difference in mean mesopic sensitivity \\\u003C\u002F=2 dB between 2 tests at screening. If not \\\u003C\u002F=2 dB, a third test may be conducted and mean values between the second and third assessments must be \\\u003C\u002F=2 dB.\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria\n\n* Participant has a history of recurrent varicella zoster virus (VZV) infection or a clinical diagnosis of VZV infection within 4 weeks of the baseline visit or positive anti-VZV immunoglobulin M (IgM). Being positive for immunoglobulin G (IgG), indicative of a past infection (or vaccination), is not an exclusionary criterion.\n* Participant has a history of recurrent cytomegalovirus (CMV) infection or a clinical diagnosis of CMV infection within 4 weeks of the baseline visit or positive anti-CMV IgM. Being positive for IgG, indicative of a past infection, is not an exclusionary criterion.\n* Participant has a positive tuberculosis (TB) test during the screening period by an interferon gamma release assay (e.g., QuantiFERON) within the 6 months prior to the screening. If a participant has tested negative for TB within the 6 months prior to the screening visit, retesting is not required unless clinically indicated.\n* Participant has a history or suspected active infection of toxoplasmosis or presence of elevated immunoglobulin M (IgM) toxoplasmosis titer within 4 weeks of the baseline visit.\n* Participant has an active infection (ocular or non-ocular) requiring the prolonged or chronic use of antimicrobial or anti-infective agents.\n* Participant has a current malignancy or history of malignancy within the past 5 years, except non-metastatic basal or squamous cell carcinoma or keratoacanthoma or Bowen's disease or carcinoma-in-situ of the cervix that has been successfully treated.\n* Participant has a history of a solid organ or bone marrow transplant.\n* Participant has any condition that would prohibit the use of systemic immunosuppression with tacrolimus.\n* Participant is receiving or has received any immunosuppressive therapy (IMT) (other than topical, inhaled or low dose systemic corticosteroid use not exceeding 7.5 mg of prednisone daily \\[or equivalent\\]) within 6 weeks or 5 plasma half-lives, whichever is longer, prior to the administration of adjunct study medications.\n* Participant has a history of myocardial infarction in previous 12 months and whose disease is either unstable and\u002For symptomatic (e.g., angina, dyspnea, etc.).\n* Participant has electrocardiogram (ECG) results that are clinically significant and could either jeopardize the safety of the participant, impact the participant's ability to comply with study visit schedule or impact the validity of the study results. Participants with a mean Fridericia-corrected QT interval of \\> 430 ms (for males) and \\> 450 ms (for females) at screening must be cleared by a cardiologist prior to the baseline visit.\n* Participant has a study day diastolic blood pressure \\> 95 mmHg, at either the screening or baseline visit. Study day blood pressure is defined as the average of the second and third readings at a study visit. If the study day blood pressure exceeds the limits, 1 additional triplicate can be taken.\n* Participant has an estimated glomerular filtration rate (eGFR) of \\\u003C\u002F= 30 mL\u002Fmin, calculated by the chronic kidney disease epidemiology collaboration (CKD-EPI) equation.\n* Participant has an alanine aminotransferase (ALT), aspartate aminotransferase (AST) or gamma- glutamyltransferase (GGT) and total bilirubin (TBL) \\>\u002F= 2 times the upper limit of normal (ULN).\n* Participant has severe anemia (hemoglobin \\\u003C 9 g\u002FdL \\[male\\] or hemoglobin \\\u003C 8 g\u002FdL \\[female\\]), leucopenia (white blood cell count \\\u003C 2500\u002Fmm\\^3), thrombocytopenia (platelet count \\\u003C 80000\u002Fmm\\^3) or polycythemia (hematocrit \\> 54% \\[male\\] or hematocrit \\> 49% \\[female\\]).\n* Participant has a hemoglobin A1c \\> 8.5%.\n* Participant has a clinically significant coagulopathy (i.e., activated partial thromboplastin time \\[aPTT\\] \\>\u002F= 1.5 times the ULN and\u002For prothrombin time adjusted for the international normalized ratio \\[PT-INR\\] \\>\u002F=2.0).\n* Participant has serology results indicative of having syphilis, Lyme disease, human immunodeficiency virus infection or active infection with hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), or varicella-zoster virus (VZV).\n* Participant has a history of familial adenomatous polyposis or inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis).\n* Participant has a history of allergic reaction to mydriatics or fluorescein.\n* Participant has a history of gene therapy or cell transplant therapy, including ASP7316, in a prior clinical study.\n* Participant has participated in any studies of an investigational drug or procedure (excluding vitamins and minerals for AMD studies) within 12 weeks prior to the screening visit, except as noted in below criterion.\n* Participant has participated with the study eye in any trial of a now FDA-approved complement inhibitor and\u002For has received an FDA approved complement inhibitor injection in the study eye within 24 weeks of the screening visit. After a washout period of 24 or more weeks, participants previously treated with a complement inhibitor will be eligible for participation, but participants will not be allowed to resume receiving any approved or investigational complement inhibitor in the study eye until the completion of the 52-week follow up period of the A7317-CL-0003 trial. Use of an FDA-approved complement inhibitor in the fellow, non-study eye is allowable.\n* Participant is unwilling to discontinue or avoid any CYP3A4 inducers (e.g., rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, St John's Wort) or participant is unwilling to discontinue or avoid protease inhibitors (e.g., nelfinavir, telaprevir, boceprevir), direct Factor Xa inhibitors, direct thrombin inhibitors, verapamil, diltiazem or erythromycin while taking tacrolimus.\n* Participant has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, opiates, cocaine, phencyclidine and methadone), unless the drug is taken for a documented medical condition and under the supervision of a physician.\n\nOcular Exclusion Criteria - Study Eye\n\n* Participant has macular degeneration due to causes other than AMD (e.g., Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.)\n* Participant has developed CNV (wet AMD), also known as exudative AMD in either eye.\n* Participant has foveal sparing as determined by the presence of potentially viable photoreceptors, as evidenced by presence of an intact ellipsoid zone (EZ) \\\u003C\u002F= 250 microns from the foveal center, based on reading center assessments at the screening visit.\n* Participant has a history of vitrectomy or submacular surgery, or any surgical intervention for AMD. Participants with a history of non-AMD-related surgical interventions (other than vitrectomy and submacular surgery) are potentially eligible if they meet all other inclusion\u002Fexclusion criteria.\n* Participant has prior treatment with photodynamic therapy (e.g., Visudyne®), intraocular external-beam radiation therapy or transpupillary thermotherapy.\n* Participant has a history of previous laser photocoagulation for choroidal neovascularization (CNV), diabetic macular edema, retinal vein occlusion and proliferative diabetic retinopathy.\n* Participant has an abnormality of vitreoretinal interface (e.g., tractional epiretinal membrane (ERM)), which can interfere with measurement of macular thickness or with the potential for macular structural damage.\n* Participant has a history of cystoid macular edema, retinal vascular occlusion, central serous chorioretinopathy, macular hole or retinoschisis in the study eye.\n* Participant has peripheral holes or other peripheral retinal lesions that are considered of rhegmatogenous potential (that is, with a risk of causing retinal detachment).\n* Participant has active or history of intraocular inflammation such as uveitis, chorioretinitis and optic neuropathy (other than glaucoma).\n* Participant has presence of an ocular toxoplasmosis scar.\n* Participant has nevus of Ota (oculodermal melanocytosis), a pigmented choroidal lesion showing characteristics associated with high risk of malignancy (e.g., elevated lesion) or a choroidal nevus in the macula.\n* Participant has pathologic myopia defined as a spherical equivalent of \\> 8.00 diopters or axial length \\> 28 mm at the screening visit, or myopic macular degeneration or posterior staphyloma.\n* Participant has glaucoma with uncontrolled intraocular pressure (IOP) (defined as IOP \\> 30 mmHg despite treatment with anti-glaucoma medication) or is using more than 2 agents to control IOP or a history of glaucoma-filtering surgery.\n* Participant has a history of corneal transplantation.\n* Participant has monocular vision; no light perception in the fellow eye or anophthalmic in the fellow eye.\n* Participant has a contraindication to pupil dilation.\n* Participant has any other ocular condition that can interfere with the assessment of imaging data.","50 Years",{"count":59,"type":20},42,[23],"Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. The advanced stage of dry AMD causes vision loss. This is known as geographic atrophy. AMD makes everyday tasks like reading or driving difficult.\n\nASP7317 is a potential new treatment for people with AMD. ASP7317 are human stem cells which have changed into cells found in the retina. ASP7317 is injected under the macula. It is hoped that ASP7317 will replace some of the damaged cells in the macula and improve vision for people with dry AMD.\n\nBefore ASP7317 is available as a treatment, the researchers need to check its safety and how well it is tolerated. They will also check for signs of improved vision. People taking part in this study will be older people who have geographic atrophy caused by dry AMD.\n\nThis is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP7317. There will be 3 doses of ASP7317. These are low, medium and high numbers of cells. ASP7317 will be injected under the macula after the person is given either a local or a general anesthetic. To prevent the body from rejecting the cells, people will take tablets of tacrolimus a few days before receiving ASP7317 for up to a few weeks afterwards. Other medicines will be taken during this time to stop infections.\n\nThere will be 2 groups in the study. Group 1 will be people with severe vision loss and Group 2 will be people with moderate vision loss. There will be different small groups of people within Group 1 and Group 2, with each small group receiving 1 of the 3 doses of ASP7317.\n\nDifferent small groups of people within Group 1 and Group 2 will receive lower to higher doses of ASP7317. Each small group will only receive 1 dose. Group 1 will start treatment first. At each dose, a medical expert panel will check the results of the first person in the group to decide if the rest of the group will receive the same dose. Then, the panel will decide if more people may receive the same dose or if the next group may receive the next highest dose. The panel will use the results from the lower dose of Group 1 to decide when Group 2 starts treatment (also at the lower dose). The panel will also use the results of the middle and higher doses in Group 1 to decide when and how many people in Group 2 can receive these doses. During the study, people will visit the clinic several times for up to 12 months (1 year).\n\nDuring all visits, the study doctors will check for any medical problems after receiving ASP7317. Vital signs will be checked a few days before treatment with ASP7317 and up to about a month afterwards. Vital signs include blood pressure, pulse, and temperature. At some visits, the study doctors will also take blood samples for blood tests. At most visits, people will have eye tests and have different images, scans, and measurements taken. This could be for the affected eye or both eyes, depending on the test. People can visit the clinic extra times, if needed.",[63],"Age-Related Macular Degeneration",[65,66,67],"Geographic Atrophy","Age-related Macular Degeneration","ASP7317","RECRUITING","2026-01-12",{"date":71,"type":42},"2026-01-13",{"date":73,"type":42},"2018-07-13",{"date":75,"type":20},"2026-06-30",{"name":48,"class":49},19,""]